CD133与CD166在脑膜瘤中的表达及意义

The expression and effect of CD133 and CD166 on meningioma

目的研究脑膜瘤中CD133与CD166标记物的表达情况及临床意义。方法选择我院诊治的40例脑膜瘤患者,运用免疫组织化学技术检测CD133和CD166标记物的情况。结果 CD133和CD166在细胞膜和细胞质中均有表达,表现为簇状或散在的聚集分布。CD133、CD166积分光密度(IOD)值在级别不同脑膜瘤患者中存在明显差异(Z=-4.080,P=0.000;Z=-4.657,P=0.000),2个指标均随着病理级别的升高而上升,表达存在明显的相关性(r=0.706,P=0.000)。结论组织病理级别与CD133和CD166表达密切相关,CD166可能是脑膜瘤干细胞的一个标记物。

Objective To investigate the expression and clinical significance of CD133 and CD166markers in meningioma patients.Methods Forty cases with meningioma in our hospital from April 2012 to April 2014 were recruited.And then the CD133 and CD166markers were tested by immunohistochemical technique.Results CD133 and CD166expressed in cell membrane and cytoplasm,which showed the presentation of clustered or scattered distribution.Integrated optical density（IOD）values of CD133 and CD166varied and differentiated with different levels of meningioma（Z=-4.080,P=0.000;Z=-4.657,P=0.000）.With the increasing pathological level,both indicators increased,of which the expressions had a significant correlation with pathological levels（r=0.706,P=0.000）.Conclusion The pathological level may be closely related to CD133 and CD166expressions,and CD166 stem cell may be a marker in meningioma.